# The Impact of the SUPPORT Act on Treatment of Opioid Use Disorder

**Authors:** Junjie Gai, Kanika Arora

PMC · DOI: 10.1093/geroni/igaf122.3397 · 2025-12-31

## TL;DR

The SUPPORT Act increased Medicare coverage for opioid use disorder treatments, leading to more medication use and outpatient services for older adults.

## Contribution

This study evaluates the causal impact of the SUPPORT Act on OUD treatment uptake among Medicare beneficiaries.

## Key findings

- Medicare beneficiaries with OUD were 11.9 percentage points more likely to receive medication treatment after the SUPPORT Act.
- Medicare beneficiaries showed a 27.1 percentage point increase in non-intensive outpatient services post-coverage expansion.

## Abstract

On January 1, 2020, Medicare Part B began covering opioid use disorder (OUD) treatments, including medications and outpatient services, under the implementation of the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities (SUPPORT) Act of 2018. However, little is known about how this coverage expansion affects OUD treatment uptake among Medicare beneficiaries. This study examines whether the passage of the SUPPORT Act influenced the likelihood of medication treatment and treatment completion for OUD patients in Medicare compared to privately insured individuals. We applied a difference-in-differences and event study methodology to examine the causal impact of the SUPPORT Act among Medicare beneficiaries with OUD. We acquired datasets from 2015 to 2022 Treatment Episodes Datasets - Discharge. Our primary outcome is a binary variable (1/0) that indicates whether the use of opioid medications such as methadone or buprenorphine is part of the treatment. Other outcomes include outpatient and inpatient service, and treatment completion rate. All analyses are clustered at the state level and adjusted by covariates. After Medicare’s coverage in 2020, Medicare beneficiaries with OUD were 11.9 percentage points (pp) more likely (p < 0.05) to receive medication for OUD relative to the privately insured group. Notably, Medicare beneficiaries are more likely to receive non-intensive services, showing a 27.1 pp increase (p < 0.05). Our findings indicate a positive significant effect of Medicare’s expanded coverage on increasing access to medication treatment and outpatient services among older adults with OUD.

## Linked entities

- **Chemicals:** methadone (PubChem CID 4095), buprenorphine (PubChem CID 644073)

---
Source: https://tomesphere.com/paper/PMC12762498